Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab

Transplant Infectious Disease

Volumn 9, Issue 1, 2007, Pages 22-27

  Silveira, F P ^a   Husain, S ^a   Kwak, E J ^a   Linden, P K ^a   Marcos, A ^a   Shapiro, R ^a   Fontes, P ^a   Marsh, J W ^a   De Vera, M ^a   Tom, K ^a   Thai, N ^a   Tan, H P ^a   Basu, A ^a   Soltys, K ^a   Paterson, D L ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Division of Infectious Diseases   (United States)

Author keywords

Alemtuzumab; Anti thymocyte globulin; Cryptococcosis; Organ transplantation

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN; FLUCYTOSINE; METHYLPREDNISOLONE; NYSTATIN; PREDNISONE; THYMOCYTE ANTIBODY; VORICONAZOLE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; FEMALE; HUMAN; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CRYPTOCOCCOSIS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS; INCIDENCE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PENNSYLVANIA; POSTOPERATIVE COMPLICATIONS; RABBITS; THYMUS GLAND;

EID: 33846989328     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2006.00149.x     Document Type: Article

References (38)

1. Brett S, Baxter G, Cooper H, Johnston JM, Tite J, Rapson N. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology 1996; 88: 13-19.
2. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004; 18: 484-490.
3. Laurenti L, Piccioni P, Tarnani M, et al. Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 153-154.
4. Parreira A, Smith J, Hows JM, et al. Immunological reconstitution after bone marrow transplant with Campath-1 treated bone marrow. Clin Exp Immunol 1987; 67: 142-150.
5. Bartosh SM, Knechtle SJ, Sollinger HW. Campath-1H use in pediatric renal transplantation. Am J Transplant 2005; 5: 1569-1573.
6. Knight RJ, Kerman RH, Podder H, Katz SM, Van Buren CT, Kahan BD. Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine. Transplant Proc 2005; 37: 1280-1282.
7. Vilchez R, Shapiro R, McCurry K, et al. Longitudinal study of cryptococcosis in adult solid-organ transplant recipients. Transpl Int 2003; 16: 336-340.
8. Paterson DL, Singh N. Cryptococcus neoformans infection. Liver Transpl 2002; 8: 846-847.
9. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001; 7: 375-381.
10. Levitz SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 1991; 13: 1163-1169.
11. Vilchez RA, Fung J, Kusne S. Cryptococcosis in organ transplant recipients: an overview. Am J Transplant 2002; 2: 575-580.
12. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34: 1098-107.
13. Goldstein E, Rambo ON. Cryptococcal infection following steroid therapy. Ann Intern Med 1962; 56: 114-120.
14. Bach MC, Sahyoun A, Adler JL, et al. High incidence of fungus infections in renal transplantation patients treated with antilymphocyte and conventional immunosuppression. Transplant Proc 1973; 5: 549-553.
15. Adamson DM, Cozad GC. Effect of antilymphocyte serum on animals experimentally infected with Histoplasma capsulatum or Cryptococcus neoformans. J Bacteriol 1969; 100: 1271-1276.
16. Perfect JR, Casadevall A. Cryptococcosis. Infect Dis Clin North Am 2002; 16: 837-874, v-vi.
17. Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis 1994; 19: 1029-1033.
18. Kovacs JA, Kovacs AA, Polis M, et al. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103: 533-538.
19. Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann Intern Med 1986; 104: 234-240.
20. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989; 321: 794-799.
21. Sorvillo F, Beall G, Turner PA, Beer VL, Kovacs AA, Kerndt PR. Incidence and factors associated with extrapulmonary cryptococcosis among persons with HIV infection in Los Angeles County. AIDS 1997; 11: 673-679.
22. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991; 4: 770-776.
23. Marcos A, Eghtesad B, Fung JJ, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004; 78: 966-971.
24. Knechtle SJ, Pirsch JD, Fechner JH Jr, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722-730.
25. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17: 77-88.
26. Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005; 74: 254-258.
27. Gonzalez H, Vernant JP, Caumes E. Successful oral valganciclovir treatment of cytomegalovirus infection during Campath-1H therapy. Leukemia 2005; 19: 478.
28. Pitini V, Arrigo C, Barresi G. Disseminated molluscum contagiosum in a patient with chronic lymphocytic leukaemia after alemtuzumab. Br J Haematol 2003; 123: 565.
29. Cavalli-Bjorkman N, Osby E, Lundin J, Kalin M, Osterborg A, Gruber A. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia. Med Oncol 2002; 19: 277-280.
30. Crowley B, Woodcock B. Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab. Br J Haematol 2002; 119: 279-280.
31. Abad S, Gyan E, Moachon L, et al. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration. Clin Infect Dis 2003; 37: e27-28.
32. Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, Dunn DL, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc 2005; 37: 934-936.
33. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (Campath 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 2005; 5: 1347-1353.
34. Jabbour N, Reyes J, Kusne S, Martin M, Fung J. Cryptococcal meningitis after liver transplantation. Transplantation 1996; 61: 146-149.
35. Singh N, Gayowski T, Wagener MM, Marino IR. Clinical spectrum of invasive cryptococcosis in liver transplant recipients receiving tacrolimus. Clin Transplant 1997; 11: 66-70.
36. Gallis HA, Berman RA, Cate TR, Hamilton JD, Gunnells JC, Stickel DL. Fungal infection following renal transplantation. Arch Intern Med 1975; 135: 1163-1172.
37. Murphy JF, McDonald FD, Dawson M, Reite A, Turcotte J, Fekety FR Jr. Factors affecting the frequency of infection in renal transplant recipients. Arch Intern Med 1976; 136: 670-677.
38. Taelman H, Bogaerts J, Batungwanayo J, Van de Perre P, Lucas S, Allen S. Failure of the cryptococcal serum antigen test to detect primary pulmonary cryptococcosis in patients infected with human immunodeficiency virus. Clin Infect Dis 1994; 18: 119-120.